Abstract
Human haemorrhoidal disease (HEM) is a common anorectal pathology. Being one of the diseases that affect a wide range of people, the etiology of HEM, as well as its molecular mechanism, remains largely unclear. In this study, we applied a two-sample bi-direction Mendelian randomisation (MR) analysis to estimate the causal effects of 4907 plasma proteins on HEM outcomes and investigated the mediating impacts of plasma proteins on HEM risk factors to uncover potential HEM treatment targets by integrating GWASs statistics of HEM and plasma protein levels. Following MR analysis, our study identified 5 probable causal proteins associated with HEM. ERLEC1 and ASPN levels were genetically predicted to be positively and inversely associated with HEM risk, respectively, with strong evidence of colocalization (H4>0.9). Furthermore, gene expression analysis of haemorrhoidal tissue and normal specimens revealed that ERLEC1 but not ASPN were differentially expressed. By analyzing single-cell ERLEC1 expression in human rectum tissues, ERLEC1 was found to be highly expressed in transient-amplifying (TA) cells. Interestingly, a genetically greater risk of myxoedema was linked to an elevated risk of HEM. However, there was no evidence that dorsalgia, hernia, diverticular disease, and ankylosing spondylitis were causally associated with HEM. Furthermore, no association was found between myxoedema and the genetically predicted ERLEC1 and ASPN levels. Overall, this study identified some causal associations of circulating proteins and risk factors with HEM by integrating the largest-to-date plasma proteome and GWASs of HEM. The findings could provide further insight into understanding biological mechanisms for HEM.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This study did not receive any funding.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Footnotes
The new version of the manuscript updated the MR analysis using only cis-pQTLs (SNPs located within a 500 kb window from the target gene body) of protein for the analysis. Correspondingly, the text and figure were also updated.
Data Availability
All data produced in the present work are contained in the manuscript.
